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Abstract
Background: Panic disorder and agoraphobia are debilitating and frequently comorbid anxiety disorders. A large
number of patients with these conditions are treated by general practitioners in primary care. Cognitive behavioural
exposure exercises have been shown to be effective in reducing anxiety symptoms. Practice team-based case
management can improve clinical outcomes for patients with chronic diseases in primary care. The present study
compares a practice team-supported, self-managed exposure programme for patients with panic disorder with or
without agoraphobia in small general practices to usual care in terms of clinical efficacy and cost-effectiveness.
Methods/Design: This is a cluster randomised controlled superiority trial with a two-arm parallel group design.
General practices represent the units of randomisation. General practitioners recruit adult patients with panic
disorder with or without agoraphobia according to the International Classification of Diseases, version 10 (ICD-10).
In the intervention group, patients receive cognitive behaviour therapy-oriented psychoeducation and instructions
to self-managed exposure exercises in four manual-based appointments with the general practitioner. A trained
health care assistant from the practice team delivers case management and is continuously monitoring symptoms
and treatment progress in ten protocol-based telephone contacts with patients. In the control group, patients receive
usual care from general practitioners. Outcomes are measured at baseline (T0), at follow-up after six months (T1), and at
follow-up after twelve months (T2). The primary outcome is clinical severity of anxiety of patients as measured by the
Beck Anxiety Inventory (BAI). To detect a standardised effect size of 0.35 at T1, 222 patients from 37 general practices
are included in each group. Secondary outcomes include anxiety-related clinical parameters and health-economic costs.
Trial registration: Current Controlled Trials [ISCRTN64669297]
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Background
Based on European epidemiological studies, the 12-
month prevalence of panic disorder (PD) is estimated at
1.8% [1]. In 35 to 65% of cases, agoraphobia is comorbid
to PD [2]. Typical clinical courses of PD and agorapho-
bia have been described as chronically recurrent and
chronically persistent, respectively [2]. Remissions without
treatment were observed in 14% of cases during the
course of seven years [3]. Both disorders reveal a disability
burden in terms of severe impairments in daily function-
ing and considerable reductions in quality of life [4]. Com-
pared to individuals without anxiety disorders, patients
suffering from panic disorder with or without agoraphobia
(PD/AG) show increased health service use and more than
three times as many work loss days [5,6]. This results in
substantial health-economic costs to society [7,8].
The prevalence of anxiety disorders is higher in rou-
tine primary care settings than in the general population
[9,10]. Current PD/AG diagnoses were found in about
4% of primary care patients [11,12]. Mental health care
for PD/AG is sought and obtained mostly from general
practitioners (GPs) [13]. At the same time, these disorders
are under-recognised and under-treated in primary care
[14,15]. Approximately half of the patients do not receive
any anxiety-specific treatment from their GPs [9,16]. Im-
provements in the management of PD/AG in routine pri-
mary care settings have been called for [12,15,17].
Evidence-based treatments of panic disorder and
agoraphobia in primary care
Both psychological and pharmacological interventions
are effective in the treatment of PD/AG [18,19]. With
regard to psychological interventions, cognitive behav-
ioural therapy (CBT) is considered the ‘gold standard’,
since meta-analyses point to its efficacy and effectiveness
for all kinds of anxiety disorders [19-21]. In case of
PD/AG, research has indicated that CBT is at least equally
effective as pharmacotherapy and can result in better long-
term effects [22-24].
According to clinical guidelines, primary care thera-
pists can deliver key-elements of CBT to patients with
PD/AG as a first step in treatment [25,26]. These key-
elements include psychoeducation (offering evidence-
based information about disorder and treatment options),
bibliotherapy (for example, written self-help books), and
motivating patients for self-managed exposure techniques
by discussion and instruction. This approach is also
known as ‘guided self-help’, where patients independently
work through a standardised psychological treatment
protocol (a so-called ‘self-help manual’), while receiving
additional guidance in terms of few therapist contacts
[27]. Meta-analyses found self-help treatments for PD/AG
to be similarly effective as traditional CBT face-to-face
therapies, since they yield moderate to large effect sizes
when compared to non-active control conditions [28-31].
However, in most of the self-help studies to date, guidance
on treatment was provided by clinical psychologists or
other mental health specialists. Few attempts have been
made to determine the efficacy of self-help treatments that
were provided by primary care therapists (for example,
GPs, health care assistants, nurses). Seekles and colleagues
performed a meta-analysis on psychological treatments of
anxiety in primary care [30]. They found small effect sizes
for treatments that were delivered by therapists who were
not specialised in mental health. Hoifodt and colleagues
reviewed studies on the effectiveness of CBT that was
delivered by primary care therapists for depression and
anxiety [32]. Although the authors found that current evi-
dence is limited, they concluded that such treatments are
potentially more effective than usual care.
Traditionally, CBT is an amalgam of behavioural and
cognitive interventions, including the following elements:
psychoeducation, coping skills, cognitive restructuring, ex-
posure exercises (that is to expose oneself sufficiently long
and repeatedly to feared stimuli whilst omitting anxiety-
reducing avoidance behaviours), and relapse prevention
[33]. Out of these elements, exposure exercises are consid-
ered essential and therapeutically most important [34].
This view is strengthened by research, showing that solely
exposure-based treatments can lead to significant clinical
improvements in patients with PD/AG [21,35-38]. Meta-
analyses compared the relative effectiveness of the differ-
ent CBT elements in the treatment of PD/AG [23,39,40].
The findings indicate that teaching coping skills, or using
cognitive restructuring, do not increase clinical outcomes
above exposure exercises alone (but see the work of
Sanchez-Meca et al.) [41]. A study by Vögele et al. dem-
onstrated beneficial changes in patients’ anxiety-related,
dysfunctional cognitions after a solely exposure-based
treatment in which no cognitive interventions were used
except for explaining the rationale of exercises [38].
Improving treatment for panic disorder and agoraphobia
in primary care by means of a practice team-supported
exposure programme
Collaborative chronic care models (CCM) provide an
evidence-based framework for improving quality of care
for patients with chronic illnesses in outpatient settings
[42-44]. CCM are aimed at enabling productive interac-
tions between prepared, pro-active practice-teams and
well-informed, motivated patients [45]. Patient self-
management support, clinical information systems, and
delivery system redesign, by means of stronger involve-
ment of non-physician practice staff in health care deliv-
ery, are recommended [43].
Studies indicated that nurse-led ‘case management’
may be a key ingredient of effective collaborative care
[46-48]. Case management has been described as a health
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worker taking responsibility for proactively following-up
patients, assessing patient adherence to treatment, moni-
toring patient progress, taking action when treatment is
not successful, and delivering patient support in close
coordination with the primary care provider, who re-
tains overall clinical responsibility [46,49,50]. A recent
meta-analysis on collaborative care for depression and
anxiety concluded that CCM can lead to greater im-
provements in anxiety outcomes than care as usual
[46]. However, only four of the included studies investi-
gated patients with PD, and in all cases study personnel
or mental health specialists were involved in patient
care [51-54]. As access to specialists is expensive and
limited in ‘real world’ primary care settings, it is im-
portant to determine the clinical effectiveness and feasi-
bility of case management approaches that can be carried
out by practice teams who are not extensively trained in
mental health care [55,56].
Aims and objectives
Clinical effectiveness of primary health care for patients
with PD/AG can potentially be improved by guiding pa-
tients to CBT-oriented exposure exercises within the
framework of practice team-based case management. Fo-
cusing on CBT-oriented exposure exercises is clearly
most promising in terms of clinical efficacy. It may fur-
ther enhance feasibility from the viewpoint of practice
teams, due to conceptual clarity. Case management pro-
cedures seem to be suitable to ensure the required safety
of patients as the course of treatment is adequately mon-
itored. If it can be shown that case management can ef-
fectively be delivered by health care assistants (HCAs),
who are already members of the practice team, possibil-
ities to increase the availability of evidence-based, low-
threshold treatments for patients with PD/AG will arise.
The aim of this study is to test the clinical efficacy
of a practice team-supported, self-managed exposure
programme for patients with PD/AG in small general
practices and to evaluate its cost-effectiveness. The study’s
primary objective is to determine whether the programme
is superior to usual care in terms of lower clinical severity
of anxiety at follow-up six months after baseline. Second-
ary objectives are to determine if the programme is super-
ior to usual care regarding further clinical parameters,
patients’ perspectives on receipt of care, and direct and in-
direct health-economic costs from a societal perspective.
Methods/design
Trial design
The study is a cluster randomised, non-blinded superior-
ity trial with two parallel groups. General practices are
treated as clusters. Allocation of clusters to two study
arms (intervention versus control) is performed with a
1:1 ratio.
Cluster randomisation has been chosen to reduce the
chance of contamination of interventions. Blinding is
not possible, due to the character of the intervention.
However, all patients should be kept blind to the alloca-
tion status, until completion of T0 baseline assessment,
in order to minimise allocation bias.
Study setting and eligibility criteria for clusters
The study is conducted in German general practices in
which the GP and at least one of his HCAs participate
in the study as a ‘practice team’. Inclusion criteria for
general practices are: (1) the GP has contracts with all
German health insurances (as 90% of care provision is
covered by this type of general practices), (2) the HCA
has been professionally trained with at least one years’
work experience, (3) GP and HCA give written consent
to study-related procedures. An exclusion criterion for
general practices is to be specialised for certain diseases
or treatments.
Eligibility criteria for individual participants
Individual participants are patients of participating general
practices who have been enroled in the study by their GPs.
To be eligible for the trial, patients have to meet the fol-
lowing inclusion criteria: (1) being at least 18 years of age,
(2) being diagnosed with PD/AG (ICD-10: F41.0 or F40.01)
by a GP-led clinical interview, (3) showing a minimum
total score on the ‘Overall Anxiety and Impairment Scale’
(OASIS) of 8 points [57] and at least two positive answers
on the panic module of the ‘Patient Health Questionnaire’
(PHQ) [11] at the time of inclusion, (4) having sufficient
German language skills, (5) having a private telephone,
(5) being capable of giving written informed consent to
participate in the study. Patients are excluded if they meet
one or more of the following exclusion criteria: suffering
from acute suicidal tendencies, acute or chronic psychosis,
dependence on psychoactive substance(s), or severe phys-
ical illness (limiting life-expectancy to less than one year or
limiting feasibility of exposure exercises); being pregnant;
receiving professional psychotherapeutic treatment for
their anxiety disorder at the time of inclusion. All eligibility
criteria for patients must be verified by the GP.
Interventions pertaining to the cluster level
All practice teams (that is in each case the GP and the
HCA of the participating general practice) are initially
trained in study procedures and documentation as well
as in clinical features of PD/AG. GPs are particularly
trained in conducting diagnostic interviews and informed
consent discussions with patients. GPs are also trained in
current treatment guidelines as usual care should meet
recommended standards [26]. Practice teams receive de-
tailed written materials concerning the imparted contents
of the training.
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All practice teams allocated to the intervention
group are additionally trained in treating patients by
use of a practice team-supported, self-managed exposure
programme. This training comprises the following con-
tents: (1) rationale of exposure techniques with regard to
PD/AG, (2) treatment plan, (3) structure of written self-
help materials, (4) targeted practice team collaboration
with the help of a monitoring checklist, (4a) only for GPs:
analysing patients’ feared stimuli, planning and imple-
menting individually appropriate exposure exercises in co-
operation with the patient, supervising treatment progress
and evaluating success of exposure exercises, possible in-
teractions of exposure exercises with psychopharmacologi-
cal treatments, (4b) only for HCAs: conducting telephone
contacts to patients with the help of a monitoring check-
list. Both the GPs and the HCAs receive detailed written
treatment manuals.
All trainings should be delivered to the practice teams
by educational workshops. In exceptional cases, where
attending a workshop is not possible, trainings may
be administered by individual Internet-based telephone
contacts using AdobeW Connect software (München,
Germany). To ensure quality of assessment, documenta-
tion and treatment of patients, general practices are con-
tacted bimonthly by members of the project team.
Interventions pertaining to the individual participants
In the intervention group, the individual treatment plan
for patients comprises four manual-based appointments
with the GP (about 30 minutes) and ten protocol-based
telephone contacts with the HCA (about ten minutes)
over a period of 23 weeks. The appointments with the
GP are aimed at delivering psychoeducation and instruc-
tions to self-managed exposure exercises. The schedule
of these appointments is described below. The tele-
phone contacts with the HCA are aimed at monitoring
anxiety symptoms and course of treatment approximately
biweekly.
Two different kinds of exposure exercises are applied
one after another: (1) interoceptive exposure, where
patients are exposed to feared bodily sensations and
(2) situational (that is in situ) exposure, where patients
are exposed to feared situations. At the start of treatment,
patients receive a newly developed self-help manual that
supports all interventions carried out by the practice team.
The self-help manual contains psychoeducational infor-
mation on PD/AG, the treatment rationale, and detailed
instructions on self-managed exposure exercises.
The contents and schedule of the manual-based ap-
pointments with the GP are as follows: appointment 1
(week 3) - psychoeducation concerning anxiety symp-
toms, appointment 2 (week 6) - psychoeducation con-
cerning avoidance behaviour and execution of individually
tailored interoceptive exposure exercises, appointment 3
(week 12) - reviewing success of interoceptive exposure
and planning of individually tailored situational exposure
exercises, appointment 4 (week 20) - reviewing success of
situational exposure and discussing methods for relapse
prevention. Patients are instructed to read the self-help
manual continuously and to practice exposure exercises at
least twice a week. Patients’ adherence to the treatment
protocol is measured by a self-report questionnaire at
follow-up T1 (Table 1).
Patients’ anxiety symptoms and adherence to treat-
ment are monitored by the HCA with the help of
a newly developed monitoring checklist (Jena-Anxiety
Monitoring List, JAMoL) during ten periodical, approxi-
mately biweekly telephone contacts. JAMoL results are
reported to the GP. If symptoms worsen or adherence is
suboptimal, the GP contacts the patient in order to
check for necessary treatment adjustments (for example,
changing planned exercises). In case of persistently se-
vere anxiety symptoms or poor adherence to treatment,
GPs are recommended to refer the patient to psychiatric
or psychological outpatient treatments. However, as the
intervention is applied in a real-world setting, GPs retain
full clinical responsibility for patients. Therefore, during
the whole course of the study, GPs may administer any
medical treatments and referrals to any in- or outpatient
treatments they deem to be useful.
In the control group, individual patients receive usual
care in consideration of recommended treatment stan-
dards. GPs retain full clinical responsibility and may
administer any medical treatments and referrals to any in-
or outpatient treatments they deem to be useful. The con-
tents of usual care during the course of the study are mea-
sured at follow-ups T1 and T2 by questionnaire (Table 1).
Outcomes
The primary outcome parameter is clinical severity of
anxiety, as measured by the widely used Beck Anxiety
Inventory (BAI) [58,59]. The German version is well-
validated. Good to excellent psychometric properties
as well as sensitivity to treatment-related changes have
been shown in primary care populations [60,61].
Secondary outcome parameters include: agoraphobic
avoidance behaviour as measured by the ‘Mobility
Inventory’ (MI; subscale ‘alone’) [62,63], number and
severity of panic attacks as measured by the ‘Panic and
Agoraphobia Scale’ (PAS; Items A1 and A2) [64,65],
depressiveness as measured by the ‘Patient Health
Questionnaire’ (PHQ-9) [66], patients’ perspectives on re-
ceipt of care as measured by the short form of the ‘Patient
Assessment of Chronic Illness Care’ questionnaire (PACIC)
[67,68], health-related quality of life as measured by the
‘EuroQol’ questionnaire (EQ-5D) [69,70], health service
use and productivity losses as measured by a modified ver-
sion of the ‘Client Sociodemographic and Service Receipt
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Inventory’ (CSSRI) [71,72], and quality adjusted life years
(QALYs) as calculated from the EQ-5D [73].
Primary and secondary outcomes are based on self-
report questionnaires that were chosen in consideration
of established validity and good psychometric properties
in primary care populations. Additional measures are
used to address characteristics of the study population,
potential confounders of efficacy parameters, or other
methodological questions. Table 1 displays the outcome
parameters and several of the additional measures. Add-
itional interview studies are planned to highlight the
feasibility and acceptability of the intervention from the
viewpoint of GPs, HCAs, and patients.
Recruitment and timeline
General practices are recruited via invitation letters. In a
first step, all general practices that are registered by
the ‘Kassenärztliche Vereinigung’ in Thuringia (Germany)
are invited to participate in the study (N = 1,251). If the re-
sponse rate turns out to be too low to meet the required
sample size, general practices from other parts of Germany
will be invited by means of public relations. Eligibility cri-
teria for general practices are checked via a questionnaire
that has to be filled out by the GP and the HCA. To be
enroled, the practice team has to give written consent to
follow the study procedures.
Patients are recruited by the participating general
practices. The recruitment procedure includes the fol-
lowing steps: (1) Patients of the general practice fill out
a screening questionnaire based on the OASIS [74] and
the PHQ panic module [11]. (2) Positively screened pa-
tients undergo a diagnostic interview conducted by the
GP, who thereby uses a diagnostic manual that is based on
validated ICD-10 checklists for PD and agoraphobia [75].
(3) If diagnosis of PD (ICD-10: F41.0) or PD/AG (ICD-10:
F40.01) is confirmed during the diagnostic interview, other
eligibility criteria for individual participants will be
checked by the GP. (4) Eligible patients are verbally in-
formed about the study by the GP who also hands out a
written information sheet to them.a (5) Eligible patients
have to sign an informed consent form to be enroled.
Each general practice is instructed that six patients
should be enroled to meet the aspired cluster size. In
order to minimise selection bias, it is intended not to
randomise a general practice before at least four patients
have already been enroled in this practice. Recruitment
of these four patients is expected within a time period of
eight to twelve weeks. However, if a general practice fails
to enrol at least four patients within this time frame,
randomisation will be performed anyway.
Baseline (T0) and follow-up (T1, T2) assessments are
administered via self-report questionnaires handed out
Table 1 Outcomes and additional measures
Measure Description Timeline
Before baseline T0 T1 T2
Primary outcome
BAI Clinical severity of anxiety • • •
Secondary outcomes
MI (subscale ‘alone’) Agoraphobic avoidance behaviour • • •
PAS (Items A1 and A2) Number and severity of panic attacks • • •
PHQ-9 Depressiveness • • •
PACIC (short form) Patients’ perspectives on receipt of care • • •
EQ-5D Health-related quality of life • • •
CSSRI (modified version) Health service use and productivity losses • • •
Additional measures
Screening questionnaire: OASIS; PHQ (panic module) Patient-reported severity of anxiety symptoms and presence of
diagnostic criteria for panic disorder
•
Diagnostic interview (ICD-10-based checklist) GP-reported diagnosis of panic disorder and agoraphobia •
Comorbid physical and mental disorders GP-reported ICD-10 diagnoses •
Sociodemographic characteristics Patient-reported age, sex, level of education, and marital status •
Treatment adherence questionnaire (self-developed) Patient-reported adherence to self-managed exposure exercises •
GPs’ usual care GP-reported referrals to psychiatric or psychological treatments
(past six months)
• •
Note. T0 = baseline before intervention; T1 = follow-up at six months; T2 = follow-up at twelve months; BAI = Beck Anxiety Inventory; CSSRI = Client Sociodemographic and
Service Receipt Inventory; EQ-5D = EuroQol questionnaire; GP = general practitioner; MI =Mobility Inventory; OASIS =Overall Anxiety Severity and Impairment Scale;
PACIC = Patient Assessment of Chronic Illness Care questionnaire; PAS = Panic and Agoraphobia Scale; PHQ= Patient Health Questionnaire. The treatment adherence
questionnaire is not administered in the control group.
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to patients by the practice teams. Subsequent to T0, the
interventions pertaining to individual participants start.
Duration of the practice team-supported, self-managed
exposure programme is about 23 weeks. Follow-up as-
sessments are six (±one) months after baseline (T1) and
twelve (±one) months after baseline (T2). Figure 1 dis-
plays the study flowchart.
Sample size
Main efficacy variable is the sum score of the BAI
(values range from 0 to 63). A former study with a
German sample of primary care patients observed a
standard deviation of 11 and an intra-cluster correlation
of 0.07 [76]. Therefore, a standardised effect size of 0.35
(that is 3.85 points on the original scale BAI) would be
observed at a significance level of 0.05 by following up
130 patients. However, cluster randomisation is the
method of choice for the present study. We expect a
cluster size of six patients per practice. In consideration
of the resulting design effect of 1.35, and the expected
patient dropout-rate of approximately 20%, N = 444
patients from 74 general practices (37 practices per
study arm) must be followed-up in order to detect a
standardised effect size of 0.35 at a significance level
of 0.05.
Assignment of interventions
Cluster randomisation of general practices is strati-
fied by population density of the administrative dis-
trict in which the practice is located (that is ‘urban
type of general practice’: urban versus rural). Computer-
assisted randomisation is prepared by the trial statisti-
cian. An uninvolved person, who is not familiar to
one of the GPs and not a member of the project team,
generates the final randomisation list. The list is pro-
vided to the data management via an online random-
isation tool.
The assignment of a certain general practice to one of
the two study arms is performed by the data manage-
ment as soon as the general practice is signalling the en-
rolment of patient(s) via fax. The data management
retrieves allocation information for the general practice
from the randomisation tool and sends it out to the gen-
eral practice via fax and phone.
Figure 1 Study flow chart.
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Data collection and management
General practices collect clinical outcome data by hand-
ing out paper-moulded case report forms (CRFs) to
patients on schedule (Figure 1). CRFs include patient
self-reports on demographic data and outcome parameters
(Table 1). As far as possible, CRFs are also handed out to
patients who discontinue or deviate from intervention pro-
tocols. To ensure quality of assessments, practice teams
are extensively trained in data collection procedures, and
onsite monitorings are conducted by the project team.
The data management periodically recalls CRFs from
general practices. CRFs are visually inspected for missing
or ambiguous self-report items. A pre-defined list of
self-explaining corrections is applied to CRFs. In cases
where self-explaining corrections are not applicable, data
queries are conducted by contacting GPs or patients.
The paper-moulded CRFs are electronically scanned and
then converted to TIF-files using ReadSofts’W FORMS
software (Helsingbord, Sweden). Subsequently, the TIF-
files are transferred to data sheets using IBM© SPSSW
software (IBM Corp., Armonk, NY, USA). Data plausibil-
ity checks are performed by the data management. Data
are retained for ten years after termination of the trial.
Statistical analyses
All analyses are based on the intention-to-treat principle,
including all enroled participants of randomised general
practices providing data under treatment. If necessary,
influence of missing data is analysed by means of add-
itional sensitivity analyses.
All population characteristics and outcome efficacy
data are presented with adequate descriptive statistics.
The primary outcome (total score of BAI at follow-up T1)
is analysed by means of a mixed linear model with general
practice as random factor and treatment group, baseline
value, and urban type of general practice as fixed factors.
According to previous research, a normal distribution can
be assumed for the present population [60]. The statistical
test is performed at a significance level of 0.05 and is
regarded as confirmatory. Estimators including 95%-confi-
dence intervals are presented. Secondary outcomes are
analysed by mixed linear models or generalised linear
models, as appropriate. The tests for secondary outcomes
are regarded as exploratory and performed at an uncor-
rected significance level of 0.05.
During the evaluation of population characteristics,
special attention is paid to the success of randomisation. In
case of major deviations, additional sensitivity analyses
with potential confounding variables are performed (for ex-
ample, age, sex, type of anxiety disorder under treatment).
With respect to the health-economic evaluation, direct
and indirect costs of the treatments in both study arms
are calculated. Administrative and market prices are
used to valuate health service use. Productivity losses are
valuated according to the human capital approach. In
terms of an effect measure, quality adjusted life years
(QALYs) are calculated from the EQ-5D [73]. A cost-
effectiveness analysis is performed from a societal per-
spective, by calculating incremental costs per QALY.
Non-parametric bootstrapping is used to estimate the
uncertainty of the incremental cost-effectiveness ratio
(ICER). Additionally, a net-monetary benefit regression
analysis is performed.
Patient safety and monitoring of adverse events
The study is planned and conducted in consideration of
Good Clinical Practice guidelines (ICH Topic E6, 2002)
as well as in accordance with the medical professional
codex and the Helsinki Declaration as updated in 2013.
Serious risks for patients are not expected as GPs provide
continuous medical care to all patients and the interven-
tions under investigation are non-invasive. However, ad-
verse events in terms of unexpected medical problems are
monitored and discussed with the studies’ scientific advis-
ory board. The occurrence of any serious adverse events
must be reported by the GPs immediately, and decisions
about continuation of the study protocol in these individ-
ual cases are made. Any decisions concerning the continu-
ation of the whole study are to be made by the principal
investigator.
Research ethics approval
The enrolment of patients did not start unless there was
a written and unrestricted positive vote of the local eth-
ics committee. The ethics committee of the Friedrich-
Schiller-University at the Medical Faculty (Jena, Germany)
approved the study protocol on 17 August 2012 (Approval
number 3484-06/12). Protocol modifications are commu-
nicated to the ethics committee by amendment.
Informed consent
Eligible patients are fully informed about the study by
their GP and a written patient information sheet is
handed out to them prior to their participation. This en-
sures that patients’ decision about participation is based
on knowledge about: anxiety diagnoses and evidence-
based therapeutic options; purpose, content, and conduct
of the study; potential benefits and risks for their health;
data management procedures; and voluntariness of partici-
pation. In case of acceptance, patients have to sign an in-
formed consent sheet to be included.a Participants may
cancel their participation at any time, without disclosing
reasons for their cancellation and without any negative
consequences regarding their future medical care.
Confidentiality of data
All personal information obtained about patients and
general practices during the recruitment process (for
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example, names, addresses, contact details) are held in
accordance to the German Federal Data Security Law
(BDSG) and medical confidentiality rules. To secure
confidentiality, these data are stored in a password-
protected server of Jena University Hospital. Paper-
based personal information is stored in a locked filing
cabinet located at the research office. Access to any per-
sonal data is strictly restricted to the project team. Per-
sonal information is never passed to any third parties.
Research numbers are assigned to general practices
and patients at the time of inclusion. Any clinical data
(as obtained by CRFs or other report forms) are
encrypted by these research numbers. Clinical data are
held strictly apart from personal data and stored on a
central server of Jena University Hospital. Encrypted clin-
ical data may be passed to project partners for analysis
purposes. In case of individual study cancellations, per-
sonal and clinical data are extinguished except that pa-
tients explicitly affirm further use.
Trial status
The trial is ongoing as the project team is still recruiting
general practices and patients.
Endnote
aPatient information sheet and informed consent form
can be obtained from the authors upon request.
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Anxiety Severity and Impairment Scale; PACIC: Patient Assessment of
Chronic Illness Care questionnaire; PAS: Panic and Agoraphobia Scale;
PHQ: Patient Health Questionnaire; PD: panic disorder; PD/AG: panic
disorder with or without agoraphobia; QALYs: quality adjusted life years.
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